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Site-speciﬁc characterization of endogenous
SUMOylation across species and organs
Ivo A. Hendriks 1, David Lyon 2, Dan Su3, Niels H. Skotte1, Jeremy A. Daniel3, Lars J. Jensen2 &
Michael L. Nielsen 1
Small ubiquitin-like modiﬁers (SUMOs) are post-translational modiﬁcations that play crucial
roles in most cellular processes. While methods exist to study exogenous SUMOylation,
large-scale characterization of endogenous SUMO2/3 has remained technically daunting.
Here, we describe a proteomics approach facilitating system-wide and in vivo identiﬁcation of
lysines modiﬁed by endogenous and native SUMO2. Using a peptide-level immunoprecipi-
tation enrichment strategy, we identify 14,869 endogenous SUMO2/3 sites in human cells
during heat stress and proteasomal inhibition, and quantitatively map 1963 SUMO sites
across eight mouse tissues. Characterization of the SUMO equilibrium highlights striking
differences in SUMO metabolism between cultured cancer cells and normal tissues. Tar-
geting preferences of SUMO2/3 vary across different organ types, coinciding with markedly
differential SUMOylation states of all enzymes involved in the SUMO conjugation cascade.
Collectively, our systemic investigation details the SUMOylation architecture across species
and organs and provides a resource of endogenous SUMOylation sites on factors important
in organ-speciﬁc functions.
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Small ubiquitin-like modiﬁers (SUMOs) are post-translational modiﬁcations (PTMs) that regulate manycellular processes1, including virtually all nuclear
functions2. SUMOylation is indispensable for eukaryotic life, and
most vertebrates express three SUMO family members, SUMO1,
SUMO2, and SUMO3. All SUMOs are conjugated by the same set
of enzymatic machinery comprising one heterodimeric E1, a
single E2, and a handful of E3 enzymes. SUMOylation is a
reversible process, and several SUMO-speciﬁc proteases exist to
facilitate removal of SUMO from lysines. SUMO2/3 are often
referred to interchangeably owing to their high degree of
homology3, and overall the SUMO machinery is conserved across
eukaryotes. In mouse, knock-out of SUMO2, which is the most
abundantly expressed out of SUMO2/3, is embryonic lethal4.
A central goal in biology is to understand the cellular
mechanisms governing biological processes, and SUMO has
emerged as an important factor in nuclear protein assemblies and
a distinguished mark for functionally engaged processes5.
Another mechanistic feature of SUMO is to spatially target
functionally related proteins6, emphasizing the importance of
understanding the substrate speciﬁcity and global regulation of
SUMOylation. Moreover, SUMO is essential for maintenance of
genome integrity and regulation of intracellular signaling. Hence,
SUMO has become an increasingly important subject of study in
biological sciences and biomedicine, with the modiﬁcation linked
to various diseases including cancer, where SUMO or the SUMO
enzymatic machinery are frequently misregulated5,7, while
SUMO-mediated transcriptional regulation is required to facil-
itate certain types of tumorigenesis8. Similarly, alterations in
SUMO regulation have been associated with ischemia9,10, Hun-
tington’s disease11, diabetes12, and heart failure13,14. As a result,
inhibitors of SUMOylation are actively being developed15, with
clinical applications in mind.
To understand the functional behavior of SUMOylation in
health and disease, it is pivotal to study SUMO at the endogenous
level and within the conﬁnes of the relevant model systems.
However, despite great biological and clinical interest, current
knowledge of endogenous and systemic regulation of SUMOy-
lation remains scarce. Although recent developments within mass
spectrometry (MS)-based proteomics have facilitated insights into
the extent of SUMOylation in cells16, these studies were based
upon introduction of exogenously expressed, epitope-tagged, and
often mutated SUMO variants. As a result, these methods are
unable to investigate endogenous SUMOylation, and infeasible
for in vivo tissue analyses without relying on genetic engineering.
Although SUMO was discovered 20 years ago17,18, the interest
in studying SUMOylation in a biomedical context using pro-
teomics approaches continues to grow. However, it has remained
technically daunting to establish analytical strategies allowing
site-speciﬁc characterization of endogenous SUMO, partly owing
to the overall low stoichiometry of SUMO, along with highly
active SUMO-speciﬁc proteases only deactivated under harsh
buffer conditions19. Additionally, when using conventional pro-
teomics approaches, digestion of SUMO2/3 with trypsin leaves a
32-residue mass tag on modiﬁed lysines, which complicates MS/
MS analysis16. Still, contemporary approaches for studying
endogenous SUMO have allowed detection of a limited number
of natively SUMOylated targets at the protein level20, or have
employed genetic engineering to purify proteins modiﬁed by
epitope-tagged SUMO from mice21–23. Further, a recent
approach identiﬁed a small number of putative endogenous
SUMO sites24. However, all current methods fail to facilitate
systems-wide analysis of speciﬁc, endogenous, native, and in vivo
SUMO2/3 sites.
Given the biomedical importance of understanding the cellular
architecture of endogenous SUMO2/3, we set out to map
SUMOylation to great depth across cells and tissues. To this end,
we developed an MS-based proteomics method that facilitates
puriﬁcation of peptides modiﬁed by endogenous, wild-type
SUMO2/3, and therein pinpoint modiﬁed lysines. The method
relies on a well-characterized antibody25, and analysis of samples
with standard MS approaches and freely available software. From
triplicate analyses of Human embryonic kidney 293 (HEK) cells,
we identiﬁed 14,869 unique SUMO2/3 sites mapping to 3870
endogenously SUMOylated proteins. However, immortalized
cancer cell lines are selected for high proliferation rates and
commonly do not represent the complex biological conditions in
tissues. Thus, in order to delineate the physiological differences in
SUMO architecture between tissues we mapped nearly 2000
SUMO2/3 sites from single-organ analyses of eight different
mouse tissues.
Collectively, we describe the largest endogenous SUMO2/3
proteomics resource to date, provide insight into the baseline
SUMOylation across cells and various organs, and highlight dif-
ferences in SUMO architecture between these highly distinct
model systems. Because our method facilitates the study of
endogenous and in vivo SUMOylation patterns in most verte-
brates, we present a ﬁnal step in equalizing the proteomics
playing ﬁeld for the system-wide study of SUMO2/3.
Results
Enrichment of endogenously SUMOylated peptides. To facil-
itate enrichment of SUMOylated peptides, we utilized the com-
mercially available SUMO2/3 8A2 antibody25, which recognizes
the C-terminus of SUMO2/3 conserved across vertebrates,
including human, mouse, chicken, Drosophila, Xenopus, and
zebraﬁsh. The antibody can also be acquired from the Develop-
mental Studies Hybridoma Bank for in-house production26, and
has previously been used to enrich endogenously SUMOylated
proteins20,26. However, despite identifying a few hundred SUMO
substrates, no modiﬁcation sites were reported.
To facilitate efﬁcient proteomics analysis of SUMO2/3-
modiﬁed lysines, we devised a peptide-level enrichment strategy
utilizing the epitope of the 8A2 antibody, mapped to reside within
the C-terminal part of SUMO2 (57-IRFRFDGQPI-66)20. We
reasoned that protein digestion using trypsin would cleave within
the epitope of SUMO2/3, thus prohibiting recognition by the 8A2
antibody, whereas digestion with endoproteinase Lys-C would
leave the epitope intact. We conﬁrmed this using dot blot analysis
of tryptic and Lys-C digests of HeLa total lysate (Supplementary
Fig. 1A–B). Moreover, as the endoproteinase Lys-C remains
active at high molar concentrations of chaotropic buffers27, this
allows samples to be rapidly lysed under denaturing conditions,
ensuring rapid inactivation of SUMO proteases and thereby
preventing loss of SUMOylation during sample preparation.
Following Lys-C digestion, all samples were desalted on C8
resin to allow efﬁcient capture of large hydrophobic peptides,
bearing in mind that the SUMO2/3 mass remnant generated
upon Lys-C digestion entails a total mass of 5.6 kDa (Supple-
mentary Fig. 1C–D). Following desalting, samples were lyophi-
lized and SUMOylated peptides were efﬁciently enriched by
SUMO-IP using the 8A2 antibody (Supplementary Fig. 2A–B).
Notably, the amount of antibody we used per milligram of
starting protein material was 20 times lower than reported
previously20 (Supplementary Note 1).
Although efﬁcient enrichment of peptides modiﬁed by
endogenous SUMO is challenging, the single-largest complication
of proteomics analysis of SUMO2/3 relates to the large mass
remnant that remains after standard protein digestion. To
alleviate this, we performed a series of pilot experiments to
establish an effective strategy entailing a second digestion step to
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complement the Lys-C digestion required for the SUMO-IP step.
Comparison of several different proteinases revealed that Asp-N
facilitated both consistent and reliable identiﬁcation of endogen-
ously SUMOylated peptides, yielding four-fold higher identiﬁca-
tion numbers compared to the other enzymes and generating a
mass remnant that uniquely identiﬁed peptides as modiﬁed by
SUMO-2/3 (Supplementary Fig. 2C–E and Supplementary
Note 1). Although our strategy entails a digestion, puriﬁcation,
followed by another digestion; serial digestion methods are widely
used in the proteomics ﬁeld16, and yield highly pure samples
when executed properly. Conclusively, we adopted a serial
digestion strategy using Lys-C and Asp-N as the main workﬂow
for the rest of our proteomics experiments (Fig. 1a).
Mapping the endogenous SUMOylome in human cells. Having
established an optimized SUMO2/3 puriﬁcation strategy, we
benchmarked our method in HEK cells by proﬁling endogenous
SUMOylation in triplicate under standard cell culture conditions,
and in response to either heat shock or the proteasomal inhibitor
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MG132 (Fig. 1b)28. All experiments were analyzed using a
streamlined MS proteomics approach (Supplementary Note 2).
Collectively, we mapped 14,869 unique endogenous SUMO2/
3 sites across the investigated cellular conditions in human cells,
with 4476 sites identiﬁed under standard growth conditions
(Fig. 1c, Supplementary Data 1 & 2). We observed an excellent
degree of reproducibility with high Pearson correlations between
same-condition replicates (Supplementary Fig. 3A), unsupervised
hierarchical clustering of same-condition replicates (Supplemen-
tary Fig. 3B), and close grouping of same-condition replicates in
principle component analysis (PCA) (Supplementary Fig. 3C).
Although not reaching the same number of identiﬁed SUMOyla-
tion sites compared to our recent study using the exogenous K0-
SUMO method2, this study nonetheless represents the largest
compendium of endogenous SUMO2/3 sites to date (Fig. 1c).
Still, we identiﬁed similar numbers of SUMO2/3 sites as
exogenous methods when performed at similar scale and cellular
background (Fig. 1d, Supplementary Note 3).
To gain insight into the overall sensitivity of our endogenous
approach, we compared the depth of sequencing achieved in our
data against other SUMO2/3 proteomics studies. To this end, we
compared the copy-numbers of identiﬁed SUMO2/3 target
proteins, by utilizing protein-per-cell copy-numbers derived from
IBAQ analysis of a deep HeLa proteome29. We found that
endogenous SUMO2/3-targeted proteins entailed a median copy-
number of 60,000, which was reassuringly similar to the largest
exogenous SUMO studies2,30, demonstrating that our strategy can
reach great depth of sequencing despite the technical challenges
associated with the study of endogenous SUMO2/3 (Fig. 1e).
Compared to previous proteomics studies focused on endogenous
SUMO20,24, our approach achieved at least 3-fold greater
sequencing depth. To emphasize that our method is not limited
in sensitivity, we additionally compared our data to a similarly-
sized group of 4391 ubiquitylated proteins identiﬁed by at least
three lysine residues31. We observed a median protein copy-
number of 100,000 for these ubiquitylated proteins, which further
supported that our method achieves good sensitivity, and suggests
that SUMOylation may systemically occur on less abundant
proteins compared to ubiquitylation.
To demonstrate that our method does not entail a sequence-
speciﬁc bias, we analyzed the adherence of identiﬁed SUMO2/
3 sites to the KxE consensus motif, as this commonly is
considered an important benchmark in SUMO proteomics
data32. We found 24.9% of all SUMOylated lysines to reside in
the KxE-type consensus motif, with 60.1% of total SUMOylation
occurring on KxE motifs (Supplementary Data 1). When only
considering sites identiﬁed under standard growth conditions,
36.4% of sites matched KxE, with 63.0% of total SUMO2/3
residing on KxE motifs. Overall, we validated our method by
reconﬁrming canonical SUMO phenomena including speciﬁc
consensus sub-motifs and distribution of sites-per-protein (Fig. 2,
Supplementary Fig. 4 and Supplementary Note 4).
Next we performed a full comparison of SUMO2/3 sites
identiﬁed in this study, to those previously reported in proteomics
screens2,19,24,28,30,33–39, in addition to SUMO sites reported in the
literature via low-throughput approaches (Supplementary Data 3).
Out of all SUMO2/3 sites we identiﬁed, 67.0% were previously
reported in screens primarily using exogenous SUMO, rising to
88.2% when looking at the top 10% highest-scoring sites.
Differences in overlap could largely be attributed to variable
protein digestion patterns, as most proteomics SUMO screens
rely on tryptic digestion, whereas we employed a Lys-C/Asp-N
approach.
We compared SUMO2/3 target proteins identiﬁed in our study
to those identiﬁed by other SUMO proteomics stu-
dies2,19,20,24,28,30,34–40. Here, we observed an overlap of 87.8%,
visualizing a higher overlap at the protein-level as compared to
the site-level, suggesting that mainly sites within the same
SUMO2/3 target proteins were identiﬁed by exogenous
approaches (Supplementary Data 4). When considering the top
10% highest-scoring SUMOylated proteins, the overlap increased
to 99.0%. Differences in the cellular SUMOylation response to
stress were quantiﬁed in HEK cells, and overall found to be
comparable to the global stress response observed in a previous
study2, with Pearson correlations of R= 0.56 and R= 0.59
between co-identiﬁed proteins and sites in response to MG132,
respectively (Supplementary Fig. 5).
A catalogue of in vivo SUMO in eight types of mouse organs.
As our method exhibited good sensitivity, we next sought to
understand the physiological differences of SUMOylation across
tissues. To this end, we performed SUMO-IP on eight types of
mouse organs—brain, heart, kidneys, lungs, liver, skeletal muscle,
spleen, and testes (Fig. 3a). Using immunoblot analysis, we vali-
dated that our SUMO-IP worked efﬁciently in mouse organs
(Supplementary Fig. 6). To properly assess reproducibility of our
method and gain quantitative insight, we performed single-organ
analyses across ﬁve wild-type animals with all organs used in their
entirety, excepting liver of which only half was analyzed.
Across all organs, we identiﬁed 1963 SUMOylation sites
(Fig. 3b and Supplementary Data 5), mapping to 955 protein-
coding genes (Supplementary Data 6). The number of SUMOyla-
tion sites per organ type appeared unrelated to the size or protein
content of the organs. Overall, we observed the highest number of
SUMOylation sites in liver, testis, kidney, and spleen, identifying
>700 SUMO2/3 sites by direct MS/MS in these organs, with up to
1131 sites in liver (Fig. 3b). The lowest numbers of SUMOylation
Fig. 1 A strategy for identifying endogenous SUMO2/3 sites. a Schematic overview of the puriﬁcation strategy. Brieﬂy, a denaturing lysate is prepared and
digested with Lys-C. Peptides are pre-puriﬁed using C8 SepPak cartridges, after which peptides are lyophilized. The peptides are then dissolved in a mild
buffer to facilitate immunoprecipitation using the 8A2 antibody. Puriﬁed SUMOylated peptides are subjected to a second round of digestion using Asp-N,
after which they are fractionated on StageTip and analyzed by nanoscale LC-MS/MS. b Experimental design for the main cell culture data. All experiments
were performed in cell culture triplicates, and analyzed as six fractions. c Overview of the total number of SUMO2/3 sites identiﬁed in this study, as
compared to several other SUMO proteomics studies. d Overview of the relative number of SUMO2/3 sites identiﬁed per condition in this study, as
compared to the largest currently published SUMO proteomics studies that used comparable cellular treatments2,30. e Estimation of depth of sequencing
through comparison of the copy-number per cell of identiﬁed proteins. IBAQ-determined copy-numbers of proteins were derived from a recent deep total
HeLa proteome study29. Protein copy-numbers were assumed to be comparable on average across different cultured human cell lines29. Top whisker: 95th
percentile, top bound: 3rd quantile, center line: median, bottom bound: 1st quantile, bottom whisker: 5th percentile. Total numbers of proteins identiﬁed are
displayed above the bars. The copy-number distribution histogram of detected proteins is overlaid for all datasets. For ubiquitin, the numbers indicate the
tested number of ubiquitylated lysines per protein, as extracted from the PhosphoSitePlus ubiquitin site database. LTP low throughput. Asterisks denote
signiﬁcant differences between SUMO2/3 target proteins identiﬁed in this study and other datasets, with blue or red asterisks indicating our study
achieved more or less depth, respectively. Determined by two-tailed Fisher’s exact testing. * P < 0.05, ** P < 0.001, x N.S
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sites were identiﬁed in heart and brain, both falling short of 200
MS/MS-identiﬁed sites. Using matching of MS1-level evidence
between experiments and organs, we were able to increase
identiﬁcation density, hereby mapping >600 SUMO2/3 sites in all
organs, >1000 sites in ﬁve organs, and up to 1309 unique sites in
liver. Accordingly, the number of sites that could be identiﬁed
across multiple organs increased considerably with the matching
data (Fig. 3c).
Globally, we observed 38.1% of SUMOylated lysine residues in
mouse organs to reside in the KxE motif, with 50.3% of all
SUMOylation occurring on these motifs. The top 100 sites
reached 67% KxE adherence, and the top 1000 sites matched
49.4% KxE (Fig. 3d), a number on par with proteomics studies
reporting equal numbers of identiﬁed SUMO2/3 sites in cell lines
under standard conditions28,39. Similar to the human SUMO2/3
data, we could conﬁrm the existence of most known SUMOyla-
tion sequence motifs within the mouse data (Fig. 3e), although we
did not observe enrichment for aspartic acid residues at −2 when
using iceLogo analysis, while threonine residues appeared
enriched from −5 to −1. To verify signiﬁcantly enriched SUMO
motifs, we additionally performed Motif-X analysis (Supplemen-
tary Data 5 and Supplementary Fig. 7), which conﬁrmed a
signiﬁcant presence of KxE-type motifs. In addition, we observed
a [ED]xKP motif, suggesting that the inverted SUMOylation
consensus motif is signiﬁcantly SUMOylated in mouse tissue
when the modiﬁed lysine is followed by a proline residue. Overall,
we found that the KxE adherence is variable between organ types,
and did not correlate with site abundance or total number of sites
(Fig. 3f). Collectively, our ﬁndings support that basic SUMO2/3
targeting preferences are comparable between cultured cells and
tissues, with some variation in number of sites and KxE
adherence between different organ types.
Functions of SUMO in organs. SUMOylation in mouse globally
adhered to functions that are canonically associated with SUMO
(Fig. 3g and Supplementary Data 7), as determined using term
annotation enrichment analysis with multiple-hypothesis cor-
rected two-tailed Fisher’s P-values to ensure an FDR of <2%. The
most enriched terms highlighted SUMO2/3 modiﬁcation of
transcription factors, chromatin regulators, numerous macro-
molecular protein complexes, and a predominantly nuclear
localization. To gain insight into SUMO target proteins across
organs, we performed label-free relative quantiﬁcation of SUMO
sites and proteins (Tables S5 and S6). Out of 1963 identiﬁed
SUMO2/3 sites and 955 SUMO2/3 target proteins, we could
quantify 46.3% and 77.8%, respectively. Reproducibility of the ﬁve
replicates was assessed using scatter plot analysis, and we
observed a high average Pearson correlation (R= 0.69) between
all same-organ replicates, with the highest reproducibility (R=
0.82) in liver (Supplementary Fig. 8A). We moreover observed
good reproducibility between the replicate animals with organs
clustering together hierarchically (Fig. 4a), and in PCA (Fig. 4b).
At the SUMO site level, hierarchical clustering and PCA analysis
additionally supported data reproducibility (Supplementary
Fig. 8B–C), and similarly outlined correlations between organ
types, with the largest deviations in the PCA observed for liver
and brain.
In order to assess whether any biological functions were
enriched for SUMOylation across organ types, we considered
SUMO2/3 target proteins inferred from MS/MS-identiﬁed SUMO
sites only, and compared the SUMOylated proteins to the
respective background proteomes for each organ type as
documented in the TISSUES database41. Subsequently, we
performed annotation enrichment analysis to extract qualitative
differences between the SUMOylated proteins and the
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background proteomes, and moreover checked whether any
enriched terms were also unique to the organ when compared to
the other tissues we analyzed (Fig. 4c and Supplementary Data 8).
All organs were enriched for many of the canonical SUMO
functions when compared to the background proteomes
(Supplementary Data 8), although we chose to focus on organ-
unique terms that were signiﬁcantly SUMO-enriched, in order to
elucidate potential organ-speciﬁc biological pathways and func-
tions signiﬁcantly regulated by SUMOylation.
Strikingly, we did not observe many unique terms to be
enriched in brain, and though core SUMO functions like nuclear
localization were enriched, this occurred less so than in all other
organs we investigated. In heart, pathways and functions related
to heart function and development were enriched for
SUMOylation. Kidney was the only other organ where we did
not observe organ-unique pathways to be enriched, likely owing
to the considerable overlap we observed with liver in terms of
SUMO2/3 sites. In liver, a range of metabolic functions were
enriched, including amino acid metabolic pathways and the urea
cycle. In lung, we observed enrichment for canonical SUMO
functions, including pathways implying a more predominant
chromatin-centric localization. We also observed SUMO enrich-
ment in lung for terms associated with myeloid leukocyte and
erythrocyte differentiation, suggesting that SUMOylation may
play a role in immune system regulation. In muscle, SUMOyla-
tion was mainly enriched on muscle-speciﬁc proteins, and
involved in glycolysis. In spleen, we observed an overall similarity
to the SUMOylome in lung, and an enrichment for pathways
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Fig. 3 Mapping the mouse SUMOylome. a Experimental design of SUMO proteomics experiments carried out in mice. Eight types of organs were studied,
in biological quintuplicate (ﬁve animals), and analyzed as six fractions. b Overview of the number of SUMO2/3 sites identiﬁed per organ, comparing direct
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04957-4
6 NATURE COMMUNICATIONS |  (2018) 9:2456 | DOI: 10.1038/s41467-018-04957-4 | www.nature.com/naturecommunications
associated with chromatin remodelers. Finally, SUMOylation in
testis was among the most distinct from all other types, with
speciﬁc SUMO modiﬁcation of proteins that are not necessarily
expressed in a tissue-speciﬁc manner. For example, we observed
strong SUMOylation enrichment for proteins associated with the
DNA damage response, mitotic recombination, helicase activity,
telomeres, and the global cellular stress response.
Although we corrected our term enrichment analysis for the
proteomes of each organ type, SUMOylation could nonetheless be
more prone to target to proteins expressed at higher levels within
the distinct tissues. To assess the extent of this effect, we
correlated elevated protein expression levels in each organ to
increased levels of SUMOylation (Fig. 4d). Comparatively,
SUMOylation in skeletal muscle and heart showed the largest
dependence on protein abundance, with modiﬁcation occurring
on proteins predominantly expressed in these organs. Conversely,
SUMOylation in brain, lung, spleen, and testis, only displayed a
modest correlation with protein abundance, further suggesting
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differences in the way SUMOylation is targeted to proteins in
these organs.
SUMOylation in human and mouse. Although considerable
differences exist between cultured human cells and mouse organs,
we sought to elucidate whether the SUMOylome would similarly
reﬂect this distinction. To this end, we performed a series of
comparisons on modiﬁed proteins (Supplementary Data 9 and
10), including subcellular localization of SUMO target proteins
(Fig. 5a, b), SUMO-phosphorylation co-modiﬁcation (Fig. 5c, d,
Supplementary Data 11 and 12), and structural targeting pre-
ference (Fig. 6a–c). All these analyses are further detailed in
Supplementary Note 5. Overall, we observed globally constant
properties of SUMOylation, including the predominant nuclear
localization, preference for modifying disordered protein regions,
and involvement of SUMO-phosphorylation co-modiﬁcation.
Since we identiﬁed a considerable number of endogenous
SUMO2/3 sites in human cells and mouse organs, we were
interested in evaluating evolutionary conservation of SUMOyla-
tion across species. Generally, the SUMO enzymatic machinery is
highly conserved across eukaryotes; however, conservation of the
individual SUMOylation sites catalyzed by the SUMO enzymes
has never been investigated on a larger scale.
We calculated Residue Conservation Scores (RCS) for all
lysines in SUMOylated proteins identiﬁed in human and mouse.
When considering RCS for all lysines, we found an average RCS
of 74.3% for lysine residues residing in globular and buried
regions, 70.9% for globular and exposed regions, and 65.4% for
disordered regions (Fig. 6d). Thus, lysines in disordered regions
are globally less conserved than lysines in ordered regions, in
agreement with what has been described previously42. Strikingly,
we found that SUMOylated lysines in ordered and exposed
protein regions were signiﬁcantly less evolutionarily conserved
compared to non-modiﬁed lysines in the same structural context
(Fig. 6e). Overall, SUMOylation preferentially targeted disordered
regions, which are intrinsically poorly conserved, and otherwise
SUMO2/3 had a tendency to modify less conserved lysines when
targeted to globular regions. Thus, we highlight a high degree of
SUMO evolution across species, in spite of the underlying
structural and sequence-speciﬁc targeting preferences being
similar between human cells and mouse tissue.
Finally, we assessed the density of SUMOylation in the
investigated samples, by quantifying the total amount of
SUMO2/3-modiﬁed peptides and proteins relative to the back-
ground signal (Supplementary Fig. 9 and Supplementary Note 6).
We observed a SUMO-IP purity of over 93% from HEK cells, and
42–62% from mouse organs. Moreover, we found that the
amount of SUMO2/3 peptides per milligram of starting material
was up to 70 times larger when purifying SUMO2/3 from HEK
cells as compared to liver, indicative of a large accumulation of
SUMO2/3 in actively cycling HEK cells.
Quantifying the native SUMO2/3 equilibrium. Within eukar-
yotic cells, SUMO proteins are expressed as immature precursors
which are processed into mature counterparts by SUMO pro-
teases43. During the SUMO conjugation cycle, the E1-E2-E3
enzymatic machinery is responsible for the reversible conjugation
of mature free SUMO to protein substrates44. However, despite
the dynamic nature of SUMO conjugation, the exact equilibrium
of SUMO pools remains relatively poorly understood, due to the
lack of analytical tools to reliably quantify distinct pools of cel-
lular SUMO. Because our method enriches the C-terminal part of
SUMO2/3 regardless of whether it is conjugated to another
protein, we were able to quantify the cellular pools of conjugated
SUMO2/3, unconjugated SUMO2/3, and immature SUMO2 and
SUMO3, in cultured cells and tissue (Fig. 7a), hereby providing
insight into the regulation of these distinct pools of SUMO.
Moreover, analysis of the conjugated pool of SUMO2/3 allows
concomitant discrimination between SUMO-chain formation,
modiﬁcation of SUMO E1 (SAE1/UBA2), E2 (UBC9), and E3
enzymes, and conjugation to any other protein.
In HEK cells, we found 93% of SUMO2/3 conjugated to target
substrates, while only 6% of SUMO2/3 existed as free SUMO
(Fig. 7b). The fraction of conjugated SUMO2/3 increased further
in response to cellular stress, up to 96% after MG132 and up to
98% after heat shock. However, considering the global pool of
conjugated SUMO2/3 increased by ~50% in response to heat
shock (Supplementary Fig. 3D), our data suggest that ongoing
synthesis of new SUMO2/3 is likely essential for the SUMO stress
response. Under control conditions, ~6% of SUMO2/3 was part
of SUMO-chains, ~3% of SUMOylation was found modifying E3
SUMO ligases, ~1% modiﬁed the E2, and only a small fraction
modiﬁed the E1. Interestingly, nearly 1% of the total SUMO pool
corresponded to immature SUMO3, which is generally consid-
ered to be expressed at a lower level than SUMO2. In response to
stress, we observed more E3 ligase modiﬁcation, indicative of
increased SUMOylation activity44. Additionally, in support of an
increased demand for SUMO maturation, the small pool of
immature SUMO2/3 that was detectable under control condition
was abolished in response to stress treatments.
Intriguingly, when quantifying the distribution of SUMOyla-
tion within mouse organs, we observed a much lower percentage
of conjugated SUMO2/3 (Fig. 7c). On average, only 52% of
SUMO2/3 was conjugated across all organs, with 47% free
SUMO2/3, ~1% immature SUMO2, and only a minor fraction of
immature SUMO3. SUMO conjugation ranged from above-
average rates of 72% and 70% in liver and lung, to below-average
rates of 21% and 35% in brain and heart, respectively.
Fig. 4 Analysis of SUMOylation across mouse organs. a Hierarchical clustering analysis of Z-scored label-free quantiﬁed (LFQ) expression values
corresponding to mouse SUMO2/3 target proteins detected across replicates and organs. Blue coloring indicates relative presence in a sample as
compared to others. b Principle component analysis (PCA) of all mouse experiments. The principle components represent the greatest degree of variability
observed within the data, and grouped experiments are generally more similar than distant experiments. Eigenvalues are displayed on the axes.
c Qualitative term enrichment analysis comparing SUMO2/3 target proteins between organs, with all SUMO target proteins inferred from
MS/MS-identiﬁed SUMO site. SUMO2/3 target proteins were compared against corresponding organ background proteomes, and only terms that were
signiﬁcantly enriched are displayed. Black text indicates terms which additionally correspond to functions that were uniquely found to be enriched in one
organ, whereas blue text indicates terms that were enriched in more than one organ. Numbers in parentheses indicate overlap between the numbers of
SUMO target proteins identiﬁed in the organ, compared to those present in the reference. Score was derived from the logarithms of enrichment ratios and
Benjamini-Hochberg FDR-corrected two-tailed Fisher’s P-values of <0.02. A full list of all enriched terms, and all relevant scores, is available in
Supplementary Data 8. d Overview of the relative expression levels of SUMO2/3 target proteins identiﬁed in each mouse organ, as compared to the
expression levels of the same proteins in the other organs. The dotted line represents a value of 1, i.e. no difference compared to other organs. Expression
levels (Mouse GeneAtlas V3) were derived from the TISSUES database41. Error bars represent SD, n= 5 animals
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Correspondingly, in brain, 78% of SUMO2/3 was observed to be
unconjugated. Strikingly, the small amount of conjugated
SUMO2/3 in brain was found to largely modify the SUMO E1
and E2 enzymes, or integrated into SUMO-chains, with less than
half of conjugated SUMO2/3 targeting other proteins. SUMOyla-
tion in testis displayed similar patterns, with 35% of SUMO2/3
residing on the E2 enzyme, 22% within SUMO-chains, and only
40% modifying other target proteins. The amount of SUMO-
chain formation in testis was signiﬁcantly higher than in all other
organs (Fig. 7c). Outside of brain and testis, SUMOylation
predominantly targeted a wider variety of substrates, similar to
HEK cells. In lung, we noted a signiﬁcantly larger SUMO2/3
fraction (4%) to modify SUMO E3 ligases compared to all other
organs (Supplementary Fig. 10), and on par with HEK cells.
Immature SUMO2 was more abundant in all mouse organs,
forming 1.2% of the total pool of SUMO2/3, contrasting HEK
cells where immature SUMO3 was more abundant. In heart,
signiﬁcantly more immature SUMO2 was measured in compar-
ison to other organs.
Taken together, we observed considerable differences in the
SUMO2/3 equilibrium, highlighting dynamic global requirements
for SUMOylation that varied signiﬁcantly between cultured cell
lines and tissues. We validated these ﬁndings using immunoblot
analyses and a distinct experimental approach (Supplementary
Fig. 11 and Supplementary Note 7). Intriguingly, considering our
tissue analyses were performed in wild-type mice, our ﬁndings
support the growing number of observations that SUMO
dynamics may be substantially enhanced in many cancers45 and
neurodegenerative diseases46. Moreover, our data indicate a
requirement for enhanced SUMO2/3 equilibrium in rapidly
proliferating cultured cells, which suggests that a high availability
and degree of conjugation of SUMO2/3 may occur in, and in turn
facilitate, proliferating cancer cells.
Endogenous SUMO chain topology. In contrast to the well-
described functions of poly-ubiquitylation47, comparatively little
is known about the functional role of poly-SUMOylation in
vertebrates48. Moreover, SUMO chains have typically been
investigated in the context of mutated and overexpressed SUMO.
Thus, we decided to investigate SUMO chain-topology under
endogenous and in vivo conditions, by extracting abundance
proﬁles for all individual SUMO linkages. In HEK cells, we
observed ~35% of SUMOylation to reside on K11 in SUMO2
(Fig. 7d), which was previously reported as the major site for
poly-SUMOylation and is the only KxE-type consensus motif in
SUMO2. Upon heat or proteotoxic stress, modiﬁcation of K11
increased further to ~50%. However, in contrast to previous
chain-topology studies2, we observed a notable degree of mod-
iﬁcation on K7, K21, and K33 in untreated cells. In response to
stress, SUMOylation on K21 and K33 was reduced. Modiﬁcation
of SUMO3 generally followed the same trend as SUMO2 (Sup-
plementary Fig. 12A), while for SUMO1, most poly-
SUMOylation by endogenous SUMO2/3 occurred via K7, which
resides in an inverted ExK-type consensus motif (Supplementary
Fig. 12B). Modiﬁcation on K7 decreased in response to cellular
stress, whereas K17, K23, K37, and K45, displayed increased
SUMOylation in response to stress. We also observed SUMO-2/3
modiﬁcation of K78 in SUMO1, with ~10% of all SUMO1 chains
occurring via this residue. K78 is the most C-terminal lysine
residue in SUMO1, and with no further lysines or arginines
towards the C-terminus it is not readily detectable using tryptic
approaches16. Although our data do not provide direct clues to
the functional role of the observed poly-SUMOylation, the chain-
topology analysis demonstrates that a wide range of lysine resi-
dues within SUMO proteins are involved in endogenous poly-
SUMO formation. Moreover, the overall abundance of SUMO
residing in poly-chains compared to the overall conjugation of
a b
dc
0
10
20
0
Spacing (number of residues)
SU
M
O
-p
ho
sp
ho
 p
ep
tid
es
 (n
um
be
r)
+5 +10 +15 >+20−5−10−15<−20
30
40
50
60
70
*
*
*
*
*
*
*
*
*
*
SU
M
O
-p
ho
sp
ho
 p
ep
tid
es
 (n
um
be
r)
0
Spacing (number of residues)
+5 +10 +15 >+20−5−10−15<−20
2
4
0
6
8
10
12
*
*
0%
20%
40%
60%
80%
100%
P
Fr
ac
tio
n 
(cu
mu
lat
ive
)
All CM Brain Heart Kidney Liver Lung Muscle Spleen Testis
PSP P P PS S S S S P P P PS S S S
SUMO
0%
P
Fr
ac
tio
n 
(cu
mu
lat
ive
)
All CM Ctrl. Heat MG132
P P P PS S S S S
20%
40%
60%
80%
100%
SUMO
Chromatin
Nucleus
Nucl / Cyto
Cyto / Mem
Cytoplasm
Membrane
Mem / Extra
Extracellular
Fig. 5 SUMO2/3 subcellular localization and SUMO-phospho co-modiﬁcation across human and mouse. a Subcellular localization analysis, based on Gene
Ontology Cellular Compartments (GOCC). All SUMO2/3 target proteins (P) and SUMO2/3 sites (S) were assigned a localization based on GOCC terms,
ranging from chromatin-associated to extracellular. Subsets of SUMO2/3 target proteins and sites were compared to each other, and to a full human
background proteome (right-most value)29, which represents all proteins present in cells. CM consensus motif (KxE). b As (a), but for SUMO2/3 target
proteins and sites identiﬁed in mouse organs. The mouse background proteome (right-most value) was derived from the TISSUES database41, covers all
eight organs, and represents all proteins present in the organs. c Schematic overview of SUMO-phospho co-modiﬁed peptides identiﬁed by MS/MS in
human cell lines. SUMOylated lysines are at position 0, with spacing indicating the residue at which phosphorylation occurred. The black line corresponds
to the average length proﬁle of all detected SUMO2/3 site peptides. Asterisks denote signiﬁcantly different values, as determined by two-tailed Fisher’s
exact testing. * P < 0.05, ** P < 0.001. d As (c), but for SUMO-phospho co-modiﬁed peptides identiﬁed by MS/MS in mouse organs
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04957-4 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:2456 | DOI: 10.1038/s41467-018-04957-4 | www.nature.com/naturecommunications 9
SUMO in cells (Fig. 7b), supported that mono-SUMOylation is
the major SUMOylation event in cultured cells.
In mouse organs, we mainly observed SUMO chain formation
on SUMO2. Strikingly, we observed a notably different SUMO2
chain topology in mouse organs, with much less modiﬁcation on
the KxE-type K11, while K21 and K33 were observed the most
highly modiﬁed. With the sequence of SUMO2 fully conserved
between human and mouse, this hints at differential regulation of
SUMO chain topology in HEK cells compared to organs. Still, the
overall relative abundance of poly-chain formation was compar-
able to HEK cells, suggesting that poly-SUMOylation may play a
consistent role across cells and organs. SUMO1 was only found to
be modiﬁed on K7 and K78, with insufﬁcient data for statistical
signiﬁcance, whereas we could not quantify SUMO3 chain
topology in mice owing to C-terminal sequence homology to
SUMO2. Moreover, N-terminal quantiﬁcation of SUMO3 was
obfuscated by two isoforms, Q9Z172-2 and G3UZA7, which we
found expressed and SUMO-modiﬁed in mouse tissues. Interest-
ingly, both of these SUMO3 isoforms differ remarkably more in
their sequence from SUMO3 than SUMO2 does, and provide
direct evidence for the existence and expression of distinct SUMO
family members in mouse organs. Overall, we observed a marked
difference in SUMO chain topology between cell culture and
mouse organs, with SUMO2 in mice being predominantly
modiﬁed on lysines other than the canonical K11, and three
distinct variants of SUMO3 being expressed and SUMO-modiﬁed
in mouse organs.
Discussion
Here, we describe a proteomics strategy facilitating the unbiased
and site-speciﬁc study of endogenous SUMO2/3, which is com-
patible with most vertebrate model systems. As a proof of prin-
ciple, we applied our method in cell culture, identifying in excess
of 14,000 SUMOylated lysines, achieving cellular depth similar to
previous studies2, but without the requirement for exogenously
expressed and mutated SUMO2/3 or other genetic engineering.
Because of this, we could utilize our strategy to proﬁle in vivo
SUMOylation across eight types of mouse organs, identifying
1963 unique SUMO2/3 sites.
Technically, our developed approach exhibits a notably
increased sequencing sensitivity compared to previous endogen-
ous SUMO methodologies20,24,49,50, and is the only method that
can speciﬁcally identify lysine residues modiﬁed by SUMO-2/3
(Supplementary Note 8). To achieve this, we utilized the 8A2
antibody to purify SUMOylated peptides, contrary to another
method that puriﬁed endogenously SUMOylated proteins20. We
reason that the increased depth achieved by our method is largely
owing to efﬁcient puriﬁcation of peptides instead of proteins, and
through puriﬁcation in very mild conditions after dissolution of
lyophilized peptides, allowing the antibody to exert its full
speciﬁcity.
Recently, a study was published that facilitates identiﬁcation of
endogenously SUMOylated lysines, through digestion of total
lysate with the wild-type α-lytic protease (WALP) enzyme fol-
lowed by di-glycine enrichment24. The WALP-only strategy has
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Fig. 7 Insight into the SUMO equilibrium. a Overview of the SUMOylation cycle, highlighting different pools of SUMO2/3 that can be quantiﬁed using our
puriﬁcation strategy. Notably, conjugated SUMO2/3 and free SUMO2/3 can be quantiﬁed, along with immature free SUMO. Conjugated SUMO2/3 was
further split into SUMO covalently conjugated to the E1, E2, or E3 enzymes, to other SUMO (chain), or to any other target protein. Note that the usual
transfer of SUMO from E1 to E2 to target requires the cysteine and does not end up on lysines within the same enzymes, but transfer to lysines in SUMO
enzymes can occur when the enzymes are active in close proximity to each other. b Quantiﬁcation of the SUMO2/3 equilibrium in human cell lines in
response to various treatments, visualizing the fraction of total SUMO existing as conjugated to certain target proteins, or as free SUMO. Error bars
represent SD, n= 3 cell culture replicates. c As (b), but quantifying the SUMO2/3 equilibrium in different mouse organs. Error bars represent SEM, n= 5
animals. Asterisks indicate signiﬁcant differences (blue, higher; red, lower) between the indicated organ and the six median organs within the same
category, by two-tailed Student’s t-test. **P < 0.001, *P < 0.05. d Quantiﬁcation of endogenous SUMO2/3 chain architecture in HEK cells in response to
various treatments, corresponding to endogenous SUMO-2 modiﬁed by SUMO-2/3. Error bars represent SD, n= 3 cell culture replicates. e As (d), but
quantifying the SUMO-2 chain architecture in different mouse organs. Error bars represent SEM, n= 5 animals
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various shortcomings, including the inability to distinguish
SUMO family members and a high potential for false-positive
identiﬁcation of ubiquitylation sites as SUMO24 (Supplementary
Note 8). In contrast to the WALP approach, our methodology
validates the presence of the SUMO2/3 mass remnant by its
unique fragmentation pattern (Supplementary Data 13 and
Supplementary Note 9). Furthermore, our strategy is at least four-
fold more sensitive compared to all data reported in other
endogenous studies24,50, while using comparable equipment, a
single fraction of a single sample, and only 60 min of MS time
(Supplementary Fig. 13).
Biologically, we observed a striking difference between the
SUMO2/3 equilibrium in cell culture and organs. In cell culture
we found the large majority of SUMO2/3 to be conjugated,
whereas considerable pools of free SUMO2/3 were observed in
mouse organs. Similar observations have previously been made
for ubiquitin, with the majority of ubiquitin conjugated in cell
culture, but a large pool of free ubiquitin existing within the
brain51. Additionally, we observed a much greater amount of total
SUMO2/3 in cell culture, relative to the total protein content.
Considering SUMO2/3 is known to be a dynamic modiﬁer, and
canonically linked to cell-cycle regulation, replication, and the
DNA damage response52, our observations suggest that rapidly
and ever-dividing cancer cells rely on the SUMOylation pathway
to maintain their genomic integrity. By contrast, cell division is
much less prominent in organs, hence SUMO2/3 is not expected
to be present or conjugated to a similarly high extent, but instead
exists as a free pool to facilitate the response to cellular stress. The
high density of SUMO2/3 in cell lines could also be a result of
continuous selection pressure, with increased amounts of endo-
genous and exogenous stresses creating a dependence on
SUMOylation to survive. Indeed, overexpression of SUMO-2/3
has previously been shown to increase the speed at which cells
divide in culture35. Ironically, whereas SUMO2/3 canonically
serves to protect faithful multiplication of the cell’s genomic
content while protecting the cell against stress, it may also ulti-
mately potentiate the rapid and uncontrolled cellular division
observed in cancer, and facilitate the dramatic changes observed
within the genomic architecture of cancer cells.
Although exhibiting differences in SUMO dynamics and den-
sity, the basic targeting preferences of SUMO did not differ
between human cells and mouse organs, with SUMOylation
predominantly occurring on KxE-type motifs, a preferential
occurrence in disordered regions of proteins, and enrichment in
the nucleus and similar spatial assemblies (Fig. 8). Still,
SUMOylation across organs targeted more speciﬁc, often organ-
unique functions, although many canonical SUMO2/3 targets
were modiﬁed across all organs. Similarly, SUMO2/3 pre-
dominantly exists as unconjugated in organs, revealing a notable
difference in SUMO2/3 equilibrium and dynamics between cul-
tured cells and organs.
Compared to other organs, SUMOylation was more prevalent
and more likely to be conjugated instead of free, in liver, lung,
spleen, and testis (Fig. 8). In liver, we identiﬁed the largest
number of sites, although partly because liver was the largest
organ analyzed. Nonetheless, SUMOylation appeared to actively
play a role in liver, modifying many liver-speciﬁc proteins and
likely inﬂuencing important metabolic pathways. In testis, we
observed the highest amount of SUMO2/3 relative to total pro-
tein, and a predominant modiﬁcation of proteins involved in the
DNA damage response and replication, which would be sup-
ported by the ongoing cell division in the form of spermato-
genesis. A high degree of E2 auto-modiﬁcation and SUMO-chain
formation was also found in testis, suggesting that SUMO mod-
iﬁcation of Ubc9 and SUMO-chain formation may play a critical
role in regulation of proteins involved in spermatogenesis.
Indeed, SUMO modiﬁcation of Ubc9 itself has previously been
shown to be important during meiosis53. Moreover, we found
ZNF451, a SUMO E3 ligase that can efﬁciently extend SUMO
chains54, to be predominantly SUMOylated in testis, suggesting
ZNF451 could be responsible for the higher degree of SUMO
chains observed in testis. In lung, we observed the highest degree
of SUMO E3 auto-modiﬁcation, often indicative of their activity.
In brain, we detected relatively few SUMOylation events, espe-
cially in relation to the size of the organ. Moreover, nearly 80% of
SUMO2/3 in brain appeared to exist in free mature state, and more
than half of conjugated SUMO2/3 was found in SUMO-chains and
on the E1 and E2 enzymes, leaving only 10% of the SUMO2/3 pool
conjugated to various target proteins. As SUMOylation commonly
is studied in the context of neurological disease, we found this
exceptionally striking. A recent publication supports our ﬁndings
and suggests that SUMO conjugation of synaptic proteins
is not only rare, but often false-positively identiﬁed55. Since we
investigated the brain SUMOylome in normal young adult mice, our
ﬁndings could imply that the SUMOylation system potentially exists
in a primed state. This is further supported by the high degree of
SUMOylation on the enzymatic machinery, which could be
indicative of high levels of SUMO-speciﬁc protease activity able to
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Fig. 8 Deﬁning the SUMO architecture. Schematic visualization of
SUMOylation phenomena observed throughout this study, ranging from
global SUMOylation properties, to model-speciﬁc and organ-speciﬁc
preferences. Globally, SUMOylation is preferentially targeted to KxE-type
consensus motifs, prefers modifying lysines residing in disordered protein
regions, and predominantly modiﬁes proteins localized in the nucleus or
otherwise enriched at spatial cellular assemblies such as nuclear bodies, the
nuclear pore complex, or at the chromatin. Depending on model system,
large variations in the SUMO2/3 equilibrium may be observed, with high
amounts of SUMO2/3 and high conjugation rates observed in rapidly
dividing cells, and only moderate amounts of SUMO2/3 and signiﬁcant
pools of unconjugated SUMO2/3 observed in normal organs. Whereas
SUMO2/3 targets virtually all nuclear cellular functions in cell culture, the
SUMO system can be more speciﬁcally tuned towards organ-speciﬁc
functions within speciﬁc tissue types. Notably enriched SUMOylated
functions were spermatogenesis-related in testis, metabolic pathways in
liver and kidney, and muscle system functions in skeletal muscle and the
heart
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rapidly reverse SUMOylation on other target proteins. In the
context of neurological stress, this standby SUMOylation system
would spring into action, potentially through temporary deacti-
vation of SUMO-speciﬁc proteases, and thereby mitigate or avert
crisis. In support of this hypothesis, the level of conjugated
SUMO2/3 is known to increase in the brain during ischemia22.
Moreover, deactivation of SUMO-speciﬁc protease SENP2 in the
nervous system has been shown to cause neurodegeneration in
mice56. However, further research using appropriate model sys-
tems will be necessary to consolidate insight into the exact reg-
ulatory function of SUMOylation in the context of neurological
disease.
Interestingly, the tissue-speciﬁc distribution of SUMO2/3 sites
in brain diverges from distribution of other PTMs. For example,
phosphorylation, glycosylation and ubiquitylation, are most
abundantly observed in brain57–59, where SUMO2/3 exhibited the
lowest modiﬁcation abundance. Our data therefore signify unique
differences in the PTM-based cellular physiology of organs as
compared to cell culture analyses where most PTMs are observed
to be highly expressed. Further discussion relating to SUMO-
chain formation, evolutionary conservation of SUMO, and organ-
speciﬁc SUMOylation patterns, is available in Supplementary
Discussion.
Collectively, we present a practical and efﬁcient strategy for
mapping the attachment sites of endogenous SUMO2/3 that will
help to pave the way for future endogenous and in vivo SUMO2/3
proteomics endeavors, with SUMO2 being the predominantly
expressed and most dynamic of all SUMO family members.
Additionally, our methodology provides quantitative insight into
baseline SUMOylation levels across multiple organs, demon-
strating marked differences in SUMO2/3 architecture compared
to cultured human cells. Moreover, the unbiased compilation of
SUMO2/3 sites identiﬁed across eight organs will serve as a
valuable resource to the ﬁeld. With enhanced SUMOylation
dynamics emerging as a general hallmark of several cancer types,
the ability of our analytical strategy to detail the SUMO archi-
tecture in disease-related tissue will ultimately enhance our
understanding of the functional role of SUMOylation in health
and disease.
Methods
Cell culture. HEK, HeLa, and U2OS cells were obtained from ATCC and routinely
tested for mycoplasma infection. The cell lines were not authenticated. Cells were
incubated at 37 °C and 5% CO2 in high Glucose GlutaMAX DMEM (Thermo
Fisher). Heat shock was performed by incubating cells at 43 °C for 1 h. Proteasome
inhibition was performed by treating cells with 10 μM of MG132
(Z-Leu-Leu-Leu-al; Sigma) for 8 h. For HeLa and U2OS cell culture replicates, ~200
million cells were cultured. For HEK cell culture replicates, ~300 million cells were
cultured.
Mice. Mouse experiments were performed in accordance with the Danish Animal
Experiments Inspectorate’s guidelines (permit no. 2012-15-2934-00346) and the
EC Directive 86/609/EEC for animal experiments. For MS experiments, ﬁve three-
month old male C57BL/6 mice were euthanized by cervical dislocation, and the
brain, heart, kidneys, lung, liver, skeletal muscle, spleen, and testes were immedi-
ately excised. Tissues were snap frozen in liquid nitrogen by dropping them into
separate 50 mL tubes containing 20 mL of liquid nitrogen, after which the tubes
containing the organs were transferred to −80 °C and stored until further pro-
cessing. For follow-up immunoblot (IB) experiments, two three-month old male
C57BL/6 mice were euthanized and processed in similar fashion.
Lysis of cells. After treatment, growth medium was decanted and cells were
immediately washed twice with ice-cold PBS. Cells were collected by gentle
scraping at 4 °C, and pelleted by centrifugation in a swing-out centrifuge at 400 × g.
Cells were washed once with ice-cold PBS prior to pelleting them again. Subse-
quently, cells were lysed in 10 pellet volumes of room temperature Lysis Buffer (6
M guanidine, 50 mM TRIS, pH 8.5), alternating vigorous vortexing and shaking to
ensure swift lysis. Cell lysates were immediately snap frozen using liquid nitrogen,
and kept at −80 °C until further processing. Lysates were thawed at room tem-
perature, and supplemented with 5 mM chloroacetamide (CAA) and 5 mM Tris(2-
carboxyethyl)phosphine (TCEP), just prior to sonication using 10 s pulses at 30W.
One pulse was used per 10 mL of lysate.
Homogenization of organs for MS and immunoblot. Frozen organs were kept on
dry ice until seconds before lysis. For MS lysis, four 1.4 mm and two 2.8 mm
zirconium beads were added per 2 mL homogenizer tube (Precellys), in addition to
10 μL of 0.5 M freshly dissolved chloroacetamide (CAA). For follow-up IB lysis,
100 μL of 0.2 M freshly dissolved N-ethylmaleimide (NEM) was added per tube
instead of CAA. Six tubes were prepared for liver, three tubes for muscle, two tubes
for brain, lungs and kidney, and one tube for testes, spleen, and heart. Larger
organs were crushed using percussive force while keeping the organs cooled on dry
ice, in order to facilitate distribution across multiple tubes. All tubes containing
beads, organs or crushed organs, and SUMO protease inhibitors, were kept on dry
ice (−80 °C) at all times. Only immediately prior to homogenization through bead-
milling, 1 mL of lysis buffer was added to all tubes. For MS sample preparation, this
buffer was identical to the one used for cultured cell lysis
(6 M guanidine, 50 mM TRIS, pH 8.5). For follow-up IB sample preparation, the
lysis buffer was composed of 2% SDS, 50 mM TRIS pH 8.5, 150 mM NaCl, freshly
supplemented with broad-range protease inhibitor cocktail (cOmplete™ Mini,
Roche) and 20 mM N-ethylmaleimide; essentially as described previously26. Bead-
milling was performed using a Precellys 24 homogenizer system, at 5500 rpm for
20 s, with organs typically already homogenized in several seconds. After each
grinding cycle, tubes were brieﬂy centrifuged at 500 × g, and subjected to another
round of grinding in case any large particulate matter remained. When lysing in
guanidine (for MS), this was only observed while homogenizing skeletal muscle.
When lysing in SDS (for IB), this was observed while homogenizing testis, spleen,
heart, and skeletal muscle. After grinding, lysates were centrifuged at 500 × g for 30
s and transferred to 15 mL tubes containing one additional volume of lysis buffer,
in order to separate homogenate from the zirconium beads. Protein concentration
was determined using standard Bradford assays for MS samples, and lysates were
diluted to 5 mg/mL using lysis buffer. For follow-up IB samples, standard BCA
assays were used instead because Bradford is incompatible with high concentra-
tions of detergent. Diluted lysates were subjected to 10 s pulses of sonication at 30
W, with one pulse used per 10 mL of total lysate volume. Following sonication, MS
lysates were supplemented with 5 mM CAA and 5mM TCEP, and incubated at 37
°C for 30 min. Reduction and alkylation was not performed for follow-up IB
samples, although alkylation by NEM is likely to have occurred during bead-
grinding in the presence of a high concentration of NEM. Next, lysates were
centrifuged for 30 min at 3000 × g in a swing-out centrifuge with delayed decel-
eration. No discernable pellets were observed after centrifugation, but rather for
some organs debris was observed to ﬂoat at the top of the samples. Thus, cen-
trifuged lysates were carefully decanted into new tubes, and subsequently passed
through 0.45 μm disc ﬁlters in order to clarify them. For follow-up IB analysis
(Supplementary Fig. 11), HEK cells were lysed similarly to mouse organs, by
pelleting the HEK cells in homogenizer tubes and snap freezing them with liquid
nitrogen, prior to subjecting them to the exact same lysis procedure as the mouse
organs.
MS lysate digestion and peptide puriﬁcation. From this point, the MS samples
preparation protocol is the same for cell line and tissue samples. Homogenized
lysates were digested by addition of Lys-C (Wako) to a 1:200 enzyme-to-protein
ratio, overnight and at room temperature. Partially-digested lysates were diluted
with 3 volumes of 50 mM ice-cold ammonium bicarbonate, gently mixed, and
allowed to warm up to room temperature. Subsequently, another round of Lys-C
digestion was performed with a 1:200 enzyme-to-protein ratio, overnight and at
room temperature. Digested lysates were acidiﬁed by addition of triﬂuoroacetic
acid (TFA) to a ﬁnal concentration of 0.5%. Acidiﬁed digests were centrifuged at
3000 × g in a swing-out centrifuge, for 30 min at 4 °C. Next, the cleared digests were
carefully decanted into new tubes. Peptides were puriﬁed using C8 Sep-Pak car-
tridges (Waters) according to the manufacturer’s instructions, using one 500 mg
sorbent Sep-Pak cartridge per 25 mg of digested protein. Prior to elution of pep-
tides, Sep-Pak cartridges were pre-eluted using 5 mL of 20% acetonitrile (ACN) in
0.1% TFA, and 3 mL of 25% ACN in 0.1% TFA. Peptides were sequentially eluted
using 1 mL 35% ACN in 0.1% TFA, 1 mL 40% ACN in 0.1% TFA, and 2 mL 45%
ACN in 0.1% TFA, after which all elutions were pooled for each replicate. Elutions
were transferred to 50 mL tubes with punctured caps, and frozen overnight at −80
°C. Deep-frozen eluted peptides were lyophilized until complete dryness, over a
period of 96 h.
Preparation of SUMO-IP beads. SUMO-IP beads were prepared up to 1 week
prior to performing the IP. A volume of 1 μL of SUMO-IP beads was used per 1 mg
of starting protein material, for all IPs performed. To prepare one batch of SUMO-
IP beads, 750 μL of Protein G Agarose beads (Roche) were washed 4× with PBS and
transferred to 1.5 mL tubes, after which 500 μL SUMO-2/3 antibody (8A2, acquired
from Abcam, ab81371; ~5–10 μg/μL antibody) was added. Tubes were ﬁlled fully
by addition of PBS, and subsequently beads and antibody were incubated in a
mixer at 4 °C for 1 h, after which the beads were washed 3× with ice-cold PBS.
Next, antibody was crosslinked to the beads by addition of 0.2 M sodium borate,
pH 9.0, freshly supplemented with 20 mM dimethyl pimelimidate (DMP), and
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incubated in a mixer for 30 min at room temperature. The crosslinking step was
repeated once, using freshly dissolved DMP. Subsequently, beads were washed
twice with ice-cold PBS, twice with room temperature 0.1 M glycine pH 2.8, and
twice with ice-cold PBS. Finally, SUMO-IP beads were stored until use, at 4 °C in
PBS supplemented with 5 mM sodium azide.
SUMOylated peptide puriﬁcation. Lyophilized peptides were dissolved in ice-
cold SUMO-IP Buffer (50 mM MOPS, 10 mM Na2HPO4, 50 mM NaCl, pH 7.2),
using 1 mL SUMO-IP Buffer per 5 mg of protein initially in the sample. Samples
were cleared by centrifugation at 3000 × g for 30 min at 4 °C, and transferred to 15
mL tubes, with no more than 10 mL of samples per tube. A volume of 50 μL of
SUMO-IP beads were added per 10 mL of sample, after which the sample was
mixed for 3 h at 4 °C. Beads were brieﬂy pelleted, transferred to 1.5 mL tubes using
ice-cold SUMO-IP buffer, and washed once more with SUMO-IP buffer. Next,
beads were washed with ice-cold PBS, transferred to clean 1.5 mL LoBind tubes
(Eppendorf), and washed once more with PBS. Subsequently, beads were washed
with ice-cold MQ water, transferred to clean 1.5 mL LoBind tubes, and washed
once more with MQ water. Peptides were eluted from the beads using two volumes
of ice-cold 0.15% TFA in MQ water, by gently mixing the beads and allowing them
to stand on ice for 30 min. The elution was repeated once, and both elutions were
pooled. Elutions were cleared by centrifugation through 0.45 μm ﬁlters, and pH-
neutralized by addition of 1/10th volume of 1M Na2HPO4. Eluted SUMOylated
peptides were frozen at −80 °C until further processing.
Second-stage digestion of SUMOylated peptides. The puriﬁed Lys-C-digested
SUMO2/3 peptides were further digested with various enzymes. All mouse samples
and the majority of all cell line samples were further digested with Asp-N (Roche),
and some initial cell line samples were digested with either trypsin (Thermo), Glu-
C (Promega), or wild-type alpha-lytic protease (WALP; Sigma). Asp-N, Glu-C, and
WALP digestions were performed in the neutralized SUMO-IP elutions, overnight
and at 30 °C, using 1 μg of enzyme per 50 mg of protein initially in the sample. For
trypsin digestion, urea was added to a ﬁnal concentration of 2M. One microgram
of trypsin per 50 mg of protein initially in the sample was used, digesting overnight
and at room temperature.
Desalting and on-StageTip high-pH fractionation. C18 StageTips were prepared
in-house2,60. For all experiments, four plugs of C18 material (Sigma-Aldrich,
Empore™ SPE Disks, C18, 47 mm) were layered per StageTip. For single-shot
samples desalted at low pH, StageTips were activated with 100 μL 100% methanol,
equilibrated with 100 μL 80% ACN in 0.5% acetic acid, and equilibrated twice with
50 μL 0.5% acetic acid, prior to loading samples. After loading, samples were
washed twice with 50 μL 0.5% acetic acid prior to elution. Samples from initial
experiments with trypsin, Glu-C, and WALP were desalted at low pH (0.5% acetic
acid) and eluted as a single sample with 50% ACN in 0.5% acetic acid. The majority
of samples prepared with trypsin, Asp-N, and WALP, were high-pH fractionated
on StageTip. For this, StageTips were conditioned with 100 μL methanol, equili-
brated with 100 μL 80% ACN in 200 mM ammonium hydroxide, and washed twice
with 75 μL 50 mM ammonium hydroxide. The pH of the digested samples was
raised by addition of ammonium hydroxide to a ﬁnal concentration of 20 mM.
Samples were loaded on StageTips, and washed twice with 75 μL 50 mM ammo-
nium hydroxide. Subsequently, six fractions (F1-6) were eluted by sequential elu-
tion with increasing amounts of ACN in 20 mM ammonium hydroxide. For Asp-N
digests, elutions were performed with 4, 7, 10, 13, 17, and 25% ACN. For trypsin
digests, elutions were performed with 5, 8, 12, 18, 27, and 50% ACN. For WALP
digests, elutions were performed with 2, 4, 7, 10, 13, and 40% ACN. Optimization
was performed on earlier experiments, and these fractions represent the ﬁnalized
proﬁles used for the majority of the samples. All fractions were completely dried in
a SpeedVac at 60 °C. Dried peptides were dissolved in 10 μL 0.1% formic acid, and
frozen at −20 °C until analysis.
Mass spectrometric analysis. Samples were analyzed on 15 cm long 75 μm
internal diameter columns, packed in-house with ReproSil-Pur 120 C18-AQ 1.9 µm
beads (Dr. Maisch), connected to an EASY-nLC 1200 system (Thermo). Column
elution was performed using a multitude of different gradients, owing to con-
siderable differences in peptide properties depending on high-pH fraction and the
enzymes used for digestion of the peptide mixtures. Settings were optimized during
earlier experiments, and the following values represent the ﬁnalized settings used
for the large majority of all samples, and for all samples that were quantiﬁed.
Single-shot samples were analyzed with 140 min effective gradient time, and
fractions with 70 min effective gradient time, with Buffer A (0.1% FA) as the initial
buffer, and an increasing amount of Buffer B (80% ACN in 0.1% FA) over time.
The following values represent the increasing value of Buffer B across the largest
time-frame of the analytical gradients, and do not include initial ramp-up and
washing blocks. Single-shot analyses; Glu-C: 5–30%, trypsin: 25–45%, WALP:
5–20%. Fraction analyses; Asp-N; F1: 13–24%, F2: 14–27%, F3–5: 15–30%, F6:
17–32%. Trypsin; F1–6: 26–42%. WALP; F1–2: 5–20%, F3–6: 5–30%. A column
heater was used to heat the column to 40 °C, and ionization was performed using a
Nanospray Flex Ion Source (Thermo). Analysis of the ion stream was performed
using a Q-Exactive HF mass spectrometer (Thermo). Spray voltage was set to 2 kV,
with a capillary temperature of 275 °C, and an S-Lens RF level of 50%. Full scans
were made at a resolution of 60,000, with an AGC target of 3,000,000 and a
maximum injection time of 60ms. The following scan ranges were used; Asp-N:
400–1600m/z, Glu-C: 300–1750m/z, trypsin: 600–1900m/z, WALP: 300–1200m/z.
Precursor fragmentation was achieved through higher-energy collision dis-
association (HCD) with a normalized collision energy of 25, an AGC target of
100,000, and an isolation width of 1.3m/z. The following precursor charge states
were considered for MS/MS; Asp-N: 2–6, Glu-C: 2–7, trypsin: 3–6, WALP: 2–5. A
dynamic exclusion of 60 s and 45 s was used for single-shot samples and fractions,
respectively. For collection and analysis of precursors by MS/MS, loop count was
set to 7, MS2 resolution to 60,000, maximum injection time to 120 ms, and
intensity threshold to 5000.
Raw data analysis. MS proteomics RAW data are available at the Proteo-
meXchange Consortium database via the Proteomics Identiﬁcations (PRIDE)
partner repository61, under dataset ID PXD008003. All RAW ﬁles were analyzed
using MaxQuant software version 1.5.3.3062,63. For the human cell line data, data
from different enzymes was analyzed in separate searches. All mouse data were
processed together in a single search. Additional searches were performed for
initial comparison between different enzymes; however, results from these were not
included in the ﬁnal processed databases. Default MaxQuant settings were used,
with exceptions and important settings outlined below. For generation of the
theoretical peptide library, the FASTA databases were downloaded from UniProt64.
The human database was downloaded on 22 February 2017, and the mouse
database on 10 May 2017. Label-free quantiﬁcation (LFQ) was enabled. For all
searches, protein N-terminal acetylation and methionine oxidation were included
as potential variable modiﬁcations (default), in addition to phosphorylation on
serine, threonine, and tyrosine. SUMO2/3 mass remnants were deﬁned as follows.
Asp-N; DVFQQQTGG, H60C41N12O15, monoisotopic mass 960.4301, neutral loss
b7-DVFQQQT, diagnostic mass remnants [b2-DV, b3-DVF, b4-DVFQ, b5-
DVFQQ, b6-DVFQQQ, b7-DVFQQQT, b9-DVFQQQTGG, QQ, FQ, FQQ]. Glu-
C, variant 1; VFQQQTGG, H49C33N9O10, monoisotopic mass 731.3602, neutral
loss b6-VFQQQT, diagnostic mass remnants [b2-VF-CO, b2-VF, b3-VFQ, b4-
VFQQ, b5-VFQQQ, b6-VFQQQT, b7-VFQQQTG, b8-VFQQQTGG]. Glu-C,
variant 2; DTIDVFQQQTGG, H77C51N13O19, monoisotopic mass 1175.5459,
neutral loss b10-DTIDVFQQQT, diagnostic mass remnants [b2-DT, b3-DTI,
b4-DTID, b5-DTIDV-H2O, b5-DTIDV, b6-DTIDVF, b7-DTIDVFQ,
b8-DTIDVFQQ, b9-DTIDVFQQQ, b10-DTIDVFQQQT]. Glu-C, variant 3;
MEDEDTIDVFQQQTGG, H105C70N17O29S1, monoisotopic mass 1679.6985,
neutral loss b14-MEDEDTIDVFQQQT, diagnostic mass remnants [b2-ME,
b3-MED, b4-MEDE, b5-MEDED, b6-MEDEDT, b6-MEDEDT-H2O,
b7-MEDEDTI, b7-MEDEDTI-H2O, b8-MEDEDTID, b8-MEDEDTID-H2O].
Glu-C, variant 3, oxidized; same as above but with one additional oxygen atom.
Trypsin, variant 1; FDGQPINETDTPAQLEMEDEDTIDVFQQQTGG,
H218C146N36O58S1, monoisotopic mass 3435.4936, neutral loss b30-FDGQPI-
NETDTPAQLEMEDEDTIDVFQQQT, diagnostic mass remnants [b4-FDGQ,
b6-FDGQPI, b7-FDGQPIN, b8-FDGQPINE, b10-FDGQPINETD, b11-FDGQPI-
NETDT, b13-FDGQPINETDTPA, b14-FDGQPINETDTPAQ, b15-FDGQPI-
NETDTPAQL, b16-FDGQPINETDTPAQLE]. Trypsin, variant 2;
FRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGG, H239C161N41O60S1, mono-
isotopic mass 3738.6632, neutral loss b32-FRFDGQPINETDTPAQLEME-
DEDTIDVFQQQT, diagnostic mass remnants [b6-FRFDGQ, b12-
FRFDGQPINETD, b13-FRFDGQPINETDT, b16-FRFDGQPINETDTPAQ, b17-
FRFDGQPINETDTPAQL, b18-FRFDGQPINETDTPAQLE, b24-FRFDGQPI-
NETDTPAQLEMEDEDT, b25-FRFDGQPINETDTPAQLEMEDEDTI, b26-
FRFDGQPINETDTPAQLEMEDEDTID, b27-FRFDGQPINETDTPAQLEME-
DEDTIDV]. The WALP mass remnant was searched as di-glycine, as it is identical
to the tryptic ubiquitin mass remnant. Enzyme cleavage speciﬁcity was set as
follows; Asp-N: C-term K and N-term D, E, up to 8 missed cleavages. Glu-C:
C-term K, D, E, up to 8 missed cleavages. Trypsin: C-term K, R, up to 4 missed
cleavages. WALP: C-term K, V, A, T, S, L, G, up to 10 missed cleavages. Minimum
peptide length was set to 7 amino acids, and maximum peptide mass was set as
follows; Asp-N: 6000 Da, Glu-C: 7000 Da, trypsin: 9000 Da, WALP: 3200 Da.
Matching between runs was performed with a match time window of 2 min and an
alignment time window of 40 min. We performed a global validation of the
matching between runs performance, which is described in Supplementary
Note 10. Data was ﬁltered for peptide-spectrum-match and protein assignment by
posterior error probability to achieve a false discovery rate of <1% (default), with a
recalibrated mass tolerance of 4.5 ppm (default). Automatic ﬁltering of modiﬁed
peptides was performed through application of a site decoy fraction of 2%, an
Andromeda score cut-off of 40 (default), and a stringent delta score cutoff of 20.
Manual ﬁltering of MaxQuant output tables. The MaxQuant output tables were
additionally manually ﬁltered for the various score values reported by Max-
Quant62,63, requiring a delta score of >40 for multiply modiﬁed peptides, a loca-
lization delta score of >6 for all modiﬁed peptides, the absence of a reversed
database hit, and the presence of diagnostic mass remnant fragments in the MS/MS
spectra corresponding to Asp-N, Glu-C, and trypsin samples. Trypsin, Glu-C and
WALP-derived SUMO sites were not allowed on peptide C-terminal lysines. Asp-
N-derived SUMO sites were allowed on peptide C-terminal lysines if the next
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residue was an aspartic acid or glutamic acid. Duplicate assignments of MS/MS
scans to multiple SUMO sites, and duplicate ±25 amino acid sequence windows
ﬂanking SUMO-modiﬁed lysines, were manually discarded. Stringent manual ﬁl-
tering resulted in discarding 13% of sites from the human Asp-N data, and 18% of
sites from the mouse Asp-N data. SUMOylated proteins were reconstructed based
on the “proteinGroups.txt” ﬁle, and only sites that remained after manual ﬁltering
were mapped back to the proteins. SUMO target proteins were deﬁned as those
with at least one SUMOylated peptide, and other proteins were discarded from
further analysis. Data pertaining to tissue-speciﬁc protein expression levels in
mouse were extracted from the TISSUES database41.
Identiﬁcation of SUMO-phospho co-modiﬁed peptides. The “evidence.txt”
output ﬁle from MaxQuant was used to ﬁlter for SUMO-phospho co-modiﬁed
peptides, and only direct MS/MS evidence was considered. A localization delta
score of >6 was demanded for both SUMOylation and phosphorylation. A com-
bined score was calculated from the excess score over Andromeda, delta, and
localization scores, primarily weighing the delta score, and co-modiﬁed peptides
were ﬁltered for a combined score of >20 (i.e. a delta score of >40), applying an
additional layer of FDR over the MaxQuant default. The highest-scoring unique
modiﬁed peptides were retained in the list, and 51 amino acid sequence windows
were assigned to both SUMOylation and phosphorylation. Quantitative informa-
tion was extracted from modiﬁcationSpeciﬁcPeptides.txt and aligned to the cor-
responding co-modiﬁed peptides.
Quantiﬁcation and scoring of SUMO sites and proteins. The n= 3 HEK data
(cell culture replicates) and n= 5 mouse data (ﬁve animals) was quantiﬁed, using
MaxQuant LFQ intensities, and requiring at least 2 peptides for quantiﬁcation of
proteins. Mouse data were median-normalized to compensate for variations in
overall protein abundance between different organs. For the HEK data, proteins
were only quantiﬁed if detected in 3 out of 3 replicates in at least one condition. For
the mouse data, proteins were only quantiﬁed if detected in at least 4 out of 5
replicates in at least one organ. After ﬁltering, missing values were globally imputed
using Perseus software65. Sites were processed and quantiﬁed analogously to the
proteins, for both HEK and mouse data. To ﬁnd signiﬁcant differences in response
to stress in the HEK data, 2-log transformed values were subjected to two-sample
testing in Perseus, with a permutation based FDR cutoff of 5% and a p0 value of 1.
To ﬁnd signiﬁcant differences between organs in the mouse data, 2-log trans-
formed values were subjected to ANOVA testing in Perseus, with a permutation
based FDR cutoff of 5% and a p0 value of 1. To visualize relative abundance of
SUMO sites and proteins, Z-scoring was performed and averaged across same-
condition replicates. For ranking of SUMO target proteins, a score was derived
from the number of SUMO sites identiﬁed in the protein, the average score of the
sites in the protein, the overall intensity of all SUMO sites, and the fraction of
SUMO site intensity compared to total protein intensity (purity). For ranking of
human SUMO sites, a score was derived from the number of MS/MS scans
identifying the site, site intensity under standard growth conditions, Andromeda
score, delta score, and the localization delta score. For mouse SUMO sites, the
number of replicates identifying the site was additionally factored into the score.
Statistical analysis and data visualization. All IceLogos were generated using the
IceLogo v1.2 tool66. For all IceLogos, reference data sets were generated based on
all proteins annotated as nuclear-localized on Uniprot, for both human and mouse
data separately. For Motif-X analyses, the online tool (http://motif-x.med.harvard.
edu) was used67, with pre-aligned foreground, lysine as the central character, a
width of 11, and otherwise default settings. Heatmaps were generated using hier-
archical clustering as integrated in Perseus software, using Z-scored values as input.
Principle component analyses were generated using Perseus, using Z-scored values
as input. All term enrichment analyses were performed using Perseus, by anno-
tating reference lists or subsets of proteins with annotation terms, and performing
two-tailed Fisher’s testing. The categories used for annotation of proteins were
Gene Ontology (GO) Biological Processes (GOBP), GO Cellular Compartments
(GOCC), GO Molecular Functions (GOMF), Kyoto Encyclopedia of Genes and
Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), Comprehensive
Resource of Mammalian protein complexes (CORUM), Protein families database
(Pfam), and a set of general keywords. Observed differences were ﬁltered for a
Benjamini–Hochberg multiple-hypotheses corrected P-value of <0.02, with P-
values acquired through two-tailed Fisher’s testing. Relative scores, only used for
the purpose of intuitive data visualization, were calculated based on the negative
base 10 logarithm of the enrichment ratio between observed and expected
adherence to terms, and on the base 2 logarithm of the FDR-corrected P-value. The
exact formula used was (Log2(enrichment)3 ×−Log10(P-value))0.25, after which
scores were normalized to 100% for the maximum value.
Quantiﬁcation of conjugated and free pools of SUMO. The mature sequence of
SUMO2 was inserted into the FASTA to allow detection of free mature SUMO2/3
in the MaxQuant searches. For quantiﬁcation of pools of SUMO, the “evidence.txt”
MaxQuant output ﬁle was used, and all peptides either modiﬁed by SUMO2/3, or
peptides derived from SUMO2/3 itself, were considered. Only evidence obtained
from Lys-C/Asp-N experiments was used. Modiﬁcation of peptides by SUMO was
sub-classed into targeting SUMO itself (chain formation), the E1 enzyme subunits
(SAE1 and UBA2), the E2 enzyme (UBC9), the E3 enzymes (any protein name
containing “E3 SUMO ligase”), or otherwise conjugation to other targets. Peptides
derived from SUMO2/3 were sub-classed as internal, mature free SUMO2/3,
immature SUMO2, or immature SUMO3. Internal peptides were considered
unknown, as they could originate from any state of SUMO, and not used for the
quantiﬁcation. Peptides ending in QQTGG (predominantly DVFQQQTGG) were
considered as mature free SUMO2/3. Peptides containing but not ending with
QQTGG were considered as immature SUMO2 (human/mouse:
DVFQQQTGGVY), or immature SUMO3 (human: DVFQQQTGGVP and
DVFQQQTGGVPESSLAGHSF, mouse: DVFQQQTGGSASRGSVPTPNRCP).
Intensities for each group were summed separately for individual replicates, and
fractions were calculated from the summed intensities and used for averages,
standard deviations, and Student’s two-tailed t-testing.
Quantiﬁcation of SUMO chains. For SUMO chain quantiﬁcation, intensity values
were directly taken from the evidence.txt ﬁle, and only evidence from Lys-C/Asp-N
experiments was considered. SUMO-modiﬁed peptides originating from SUMO1,
SUMO2, and SUMO3, were isolated and binned based on modiﬁed lysines. In case
multiple lysines were simultaneously modiﬁed, the peptide intensity was added to
each site. Summed site intensities were converted to fractional values within each
replicate, and fractional values were averaged across replicates and used for further
statistical calculations.
Structural prediction. 3870 human and 955 mouse SUMO target proteins were
subjected to structural predictive analysis. The IUPred workﬂow was used68 to
determine disordered (D-type) or globular (G-type) regions in the proteins. the
ACCpro workﬂow was used69 to determine solvent-exposed (E-type) or buried (B-
type) regions in the proteins. All disordered lysines were considered exposed,
resulting in three classiﬁcations for all lysines: D-type, globular/exposed (GE-type)
and globular/buried (GB-type).
Evolutionary conservation analysis. Human and mouse Uniprot accession
numbers were mapped to ENSP identiﬁers using “full_uniprot_2_string.04_2015.
tsv” derived from STRING70, in addition to the “Retrieve/ID mapping” function-
ality from Uniprot64. Multiple sequence alignments (MSA) of the mammalian
orthologous group (OG), their corresponding ENSP identiﬁers, and ﬁne-grained
orthologs (FGO), were retrieved from eggNOG71. ENSP identiﬁers were mapped to
eggNOG group names via “maNOG.members.tsv”, and FGO pairs between human
and mouse were retrieved via the eggNOG REST API, thereby mapping Uniprot to
ENSP identiﬁers and determining ﬁne-grained orthologous proteins between
human and mouse. In order to obtain a metric for evolutionary conservation,
Residue Conservation Scores (RCS) were calculated72, using MSA derived from
eggNOG and the following parameters; method was set to “trident”, matrix to
“blosum62”, diversity to 1, chemistry to 0.5, and a gap penalty of 2 was used. This
resulted in RCS values for all amino acid residues within the MSA. In order to
evaluate differences between evolutionary conservation of SUMOylated and non-
SUMOylated lysine residues, we performed a two-tailed paired Student’s t-test on
the aforementioned RCS values, while correcting for disordered, globular-exposed,
and globular-buried regions. P-values <0.001 were deemed signiﬁcant.
Comparison of proteomic SUMO studies. In order to align human SUMO target
proteins, a scaffold was created based on all unique protein-coding genes as
downloaded from UniProt on 16 July 2017. Protein identiﬁer and protein names
were imported, along with basic protein size and mass information. SUMO target
proteins identiﬁed in this study were aligned to the scaffold, along with SUMO
target proteins identiﬁed in other SUMO proteomics studies2,19,20,24,28,30,34–40, and
proteins identiﬁed in two total proteome studies29,73. Alignment was primarily
performed using Uniprot identiﬁer, and otherwise protein-coding gene. For
comparison of human SUMO sites, a scaffold was generated from all 51 amino acid
sequence windows derived from this study, as well as 51 amino acid sequence
windows identiﬁed in other SUMO proteomics studies2,19,24,28,30,33–39. Duplicate
51 amino acid sequences were excluded, and afterwards all studies were indivi-
dually mapped to the scaffold. Qualitative and quantitative information from this
study, and from one previous SUMO proteomics study, was aligned to the data-
base. Information on low-throughput-identiﬁed SUMO sites, ubiquitylation sites,
acetylation sites, and methylation sites, was extracted from PhosphoSitePlus on 19
July 2017, and aligned to the database.
Immunoblot and dot blot analyses. Dot blot (slot blot) analyses were performed
using a Slot Blot Manifold PR648 system (Thermo) connected to a vacuum pump.
To assist in capture and visualization of peptides and small proteins, supported
nitrocellulose membranes with 0.2 μm pore-size were used (Protran, Amersham) in
the dot blot system. Samples were loaded and subsequently transferred onto the
membranes by application of a mild vacuum for ~15 s. For 1D gel electrophoresis,
samples were supplemented with 1/3rd volume of NuPAGE™ LDS Sample Buffer
(4×), dithiothreitol was added to a ﬁnal concentration of 100 mM, and samples
were incubated at 70 °C for 10 min prior to loading. Peptides were separated on
NuPAGE 4–12% Bis-Tris gradient gels (Thermo), using MES buffer to assist
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separation of peptides and small proteins. Proteins were separated on the same
gradient gels, but using MOPS buffer. Electrophoretic separation was achieved
using XCell SureLock™ Mini-Cell Electrophoresis systems (Thermo), set to 80 V for
10 min and then 200 V until the loading dye front reached the bottom of the gel
(~45 min). To assist in capture and visualization of peptides and small proteins,
supported nitrocellulose membranes with 0.2 μm pore-size were used (Protran,
Amersham) for immunoblot transfer. Subsequently, XCell SureLock™ Mini-Cell
Electrophoresis systems were used to transfer peptides or proteins from the gels to
the nitrocellulose membranes. For peptides, transfer buffer contained 25 mM TRIS,
192 mM glycine, and 20% methanol. For proteins, transfer buffer contained 50 mM
TRIS, 384 mM glycine, and 10% methanol. For peptides, transfer was performed
ice-cold for 1 h at 20 V and 2 h at 25 V. For proteins, transfer was performed ice-
cold for 1 h at 25 V, 1 h at 30 V, and 1 h at 35 V. At this stage, membranes acquired
either through dot blot (vacuum) transfer or electrophoretic transfer, were handled
similarly. Membranes were rinsed with MQ water, and subsequently incubated
with Ponceau-S solution (Sigma) for 1 min. After incubation, membranes were
rinsed three times with MQ water and kept in 0.1% acetic acid to stabilize Ponceau-
S stain during scanning of the membranes. Subsequently, Ponceau-S was rinsed off
the membranes by incubation in PBS supplemented with 0.1% Tween-20 (Sigma);
PBST. Membranes were blocked for 1 h at room temperature using 8% (w/v) skim
milk powder in PBST (8% milk), after which incubation with primary antibody
occurred overnight in 8% milk at 4 °C. Subsequently, membranes were washed
three times 10 min with ice-cold PBST, re-blocked for 30 min with 10% milk at 4 °
C, incubated with secondary antibody in 10% milk at 4 °C, washed three times 20
min with ice-cold PBST, and washed three times 10 min with ice-cold PBS.
Visualization was achieved using enhanced chemiluminescence kits (Novex)
according to the manufacturer’s instructions. Chemiluminescence was captured
using Amersham Hyperﬁlm ECL (Sigma). Anti-SUMO2/3 8A2 antibody (Abcam,
ab81371) was used as the primary antibody at a 1:2500 concentration in all cases.
Goat-anti-mouse HRP conjugated secondary antibody (Jackson Immunoresearch,
115–035–003) was used at a concentration of 1:2500. All scans of immunoblots and
Ponceau-S-stained membranes displayed in this manuscript are uncropped and
display the full molecular weight range.
Data availability. Mass spectrometry RAW data are available at the Proteo-
meXchange Consortium database via the Proteomics Identiﬁcations (PRIDE)
partner repository, under dataset ID PXD008003. Other data can be obtained from
the corresponding author upon reasonable request.
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